Clynav (pUK-SPDV-poly2#1 DNA plasmid coding...) - QI10AX
Updated on site: 09-Feb-2018
|Наименование на лекарството:||Clynav|
|Вещество:||pUK-SPDV-poly2#1 DNA plasmid coding for salmon pancreas disease virus proteins|
|Производител:||Elanco Europe Limited|
Съдържание на статията
salmon pancreas disease vaccine (recombinant DNA plasmid)
This is a summary of the European public assessment report (EPAR) for Clynav. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Clynav.
For practical information about using Clynav, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
What is Clynav and what is it used for?
Clynav is a veterinary vaccine used in Atlantic salmon to protect them against pancreas disease caused by salmonid alphavirus subtype 3 (SAV3). Pancreas disease in Atlantic salmon can lead to impaired daily weight gain, lesions of the heart, pancreas and skeletal muscle as well as death.
Clynav contains as active substance a DNA plasmid (a small piece of DNA) containing the genetic code for making salmon pancreas disease virus proteins.
For further information, see the package leaflet.
How is Clynav used?
Clynav is available as a solution for injection and can only be obtained with a prescription.
The vaccine is given to anaesthetised fish as a single injection into epaxial muscle (muscle of the upper half of the fish) in the area to the front and side of the dorsal fin. The time for protection to develop following vaccination depends on the water temperature: protection starts within 399 degree days, calculated as mean water temperature in °C multiplied by number of days, for example 40 days at a water temperature of 10 °C. Protection lasts approximately three months after vaccination at average water temperature of 12 ±2 °C.
How does Clynav work?
Clynav is a DNA vaccine. Vaccines work by ‘teaching’ the immune system (the body’s natural defences)
how to defend itself against a disease. Clynav contains a DNA plasmid which, once injected into fish, will lead to the production of salmon pancreas disease virus (SPDV) proteins. The immune system recognises these virus proteins as ‘foreign’ and makes defences against them. In the future, if the fish are exposed to the virus, the immune system will be able to respond more quickly. This will help to protect against the disease.
What benefits of Clynav have been shown in studies?
Six laboratory studies were conducted in fresh water and sea water to show how effective the vaccine was in protecting salmon from disease caused by SPDV. A main laboratory model study looked at the signs of pancreas disease in fish given Clynav compared with a dummy saline injection. Following artificial infection by
What are the risks associated with Clynav?
The most common side effects with Clynav (which may affect more than 1 in 10 fish) are short lived changes in swimming behaviour for up to two days, altered pigmentation (colouration) for up to seven days and lack of appetite for up to nine days. Needle injuries at the site of injection are common following vaccination and can persist for at least 90 days.
For the full list of all side effects reported with Clynav, see the package leaflet.
What are the precautions for the person who gives the medicine or comes into contact with the animal?
Direct contact should be avoided and protective equipment (for example protective gloves) should be worn when handling the medicine.
In case of accidental needle stick or
What is the withdrawal period in
The withdrawal period is the time required after administration of a medicine before an animal can be slaughtered and the meat used for human consumption.
The withdrawal period for fish from Atlantic salmon treated with Clynav is ‘zero’ days, which means there is no mandatory waiting time.
Why is Clynav approved?
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Clynav’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Other information about Clynav:
The European Commission granted a marketing authorisation valid throughout the EU for Clynav on 27/06/2017.
The full EPAR for Clynav can be found on the Agency’s website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports. For more information about treatment with Clynav, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
This summary was last updated in April 2016.